Die US-Arzneimittelbehörde FDA Food and Drug Administration empfiehlt, den Hepatitis-C – Proteasehemmer Boceprevir (Handelsname Victrelis) nicht mir Ritonavir-verstärkten HIV-Proteasehemmern zu kombinieren. Hintergrund sind Wechselwirkungen, die zu gegenseitigen Wirkungsbeeinträchtigungen führen können:
„The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. Ritonavir-boosted HIV protease inhibitors include ritonavir-boosted Reyataz (atazanavir), ritonavir-boosted Prezista (darunavir), and Kaletra (lopinavir/ritonavir).“
Hersteller Merck teilte mit, man plane eine größere Studie, in der die Wechselwirkungen von Boceprevir mit HIV-Medikamenten untersucht werden sollen.
FDA 26.04.2012: FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
FDA 08.02.2012: FDA Drug Safety Communication: Important drug interactions between Victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs